Механизмы развития и пути преодоления эндокринной резистентности при раке молочной железы
Об авторахАртур Альбертович Хисамов
Ольга Олеговна Мануйлова
зам. заведующего Клиники женского здоровья,
Михаил Юрьевич Бяхов
д.м.н., профессор, зам. директора по онкологии,
1. “World Cancer Report”. International Agency for Research on Cancer. 2008. Retrieved 2011–02–26.
2. S.R.D. Johnston and M. Dowsett, “Aromatase inhibitors for breast cancer: lessons from the laboratory,” Nature Reviews Cancer, vol. 3, no. 11, pp. 821–831, 2003.
3. A. A. Larionov and W.R. Miller, “Challenges in defining predictive markers for response to endocrine therapy in breast cancer,” Future Oncology, vol. 5, no. 9, pp. 1415–1428, 2009.
4. Clark GM, Osborne CK, McGuire WL. 1984. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J. Clin. Oncol. 2: 1102–9.
5. Wenger CR, Beardslee S, Owens MA, et al. 1993. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res. Treat. 28: 9–20.
6. Schiff R, Osborne CK, Fuqua SA. 2009. Clinical aspects of estrogen and progesterone receptors. In Diseases of the Breast, ed. JR Harris, ME Lippman, M Morrow, CK Osborne, pp. 408–30. Philadelphia: Wolters Kluwer/LippincottWilliams & Wilkins. 4th ed.
7. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233–47. doi: 10.1146/annurev-med-070909–182917. Review.
8. J. M. Dixon. Endocrine Resistance in Breast Cancer. New Journal of Science. Volume 2014, Article ID390618, 27 pages. http://dx.doi.org/10.1155/2014/390618
9. E. R. Simpson and M. Dowsett. Aromatase and its inhibitors: significance for breast cancer therapy. Recent Progress in Hormone Research, vol. 57, pp. 317–338, 2002.
10. A.A. Larionov, D.A. Vasyliev, J. I. Mason, A. F. Howie, L.M. Berstein, and W.R. Miller, “Aromatase in skeletal muscle,” Journal of Steroid Biochemistry and Molecular Biology, vol. 84, no. 4, pp. 485–492, 2003.
11. E. Perel and D.W. Killinger. The interconversion and aromatization of androgens by human adipose tissue. Journal of Steroid Biochemistry, vol. 10, no. 6, pp. 623–627, 1979.
12. C. Longcope, J.H. Pratt, S.H. Schneider, and S. E. Fineberg, “Aromatization of androgens by muscle and adipose tissue in vivo,” Journal of Clinical Endocrinology andMetabolism, vol. 46, no. 1, pp. 146–152, 1978.
13. H. Sasano, M. Uzuki, T. Sawai et al. Aromatase in human bone tissue. Journal of Bone andMineral Research, vol. 12, no. 9, pp. 1416–1423, 1997.
14. W.R. Miller and A. P.M. Forrest, “Oestradiol synthesis by a human breast carcinoma,” The Lancet, vol. 2, no. 7885, pp. 866–868, 1974.
15. J.R. Pasqualini, G. Chetrite, C. Blacker et al., “Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 4, pp. 1460–1464, 1996.
16. T. J. Key, “Endogenous sex hormones and breast cancer in postmenopausalwomen: reanalysis of nine prospective studies,” Journal of the National Cancer Institute, vol. 94, no. 8, pp. 606–616, 2002.
17. W.R. Miller and J. O’Neill, “The importance of local synthesis of estrogen within the breast,” Steroids, vol. 50, no. 4–6, pp. 537–548, 1987. S. E. Bulun, G. Sharda, J. Rink, S. Sharma, and E.R. Simpson, “Distribution of aromatase p450 transcripts and adipose fibroblasts in the human breast,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 3, pp. 1273–1277, 1996.
18. N. Harada, T. Utsumi, andY.Takagi, “Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissuespecific exons 1 in carcinogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no.23, pp. 11312–11316, 1993.
19. M.P. Schrey and K.V. Patel, “Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators,” British Journal of Cancer, vol. 72, no. 6, pp. 1412–1419, 1995.
20. C.M. Klinge, “Estrogen receptor interaction with estrogen response elements,” Nucleic Acids Research, vol. 29, no. 14, pp. 2905–2919, 2001.
21. V. Kumar, S. Green, G. Stack, M. Berry, J. Jin, and P. Chambon, “Functional domains of the human estrogen receptor,” Cell, vol. 51, no. 6, pp. 941–951, 1987.
22. M. Beato, “Gene regulation by steroid hormones,” Cell, vol. 56, no. 3, pp. 335–344, 1989.
23. M. Tsai and B.W.O’Malley, “Molecularmechanisms of action of steroid/thyroid receptor superfamily members,” Annual Review of Biochemistry, vol. 63, pp. 451–486, 1994.
24. S. Kato, H. Endoh, Y. Masuhiro et al., “Activationof the estrogen receptor through phosphorylation by mitoqenactivated protein kinase,” Science, vol. 270, no. 5241, pp. 1491–1494, 1995.
25. A. E. Wakeling, “Similarities and distinctions in the mode of action of different classes of antioestrogens,” EndocrineRelated Cancer, vol. 7, no. 1, pp. 17–28, 2000.
26. G. Reid, M.R. Hubner, R. Metivier et al., “Cyclic, proteasomemediated turnover of unliganded and liganded ER on responsive promoters is an integral feature of estrogen signaling,” Molecular Cell, vol. 11, no. 3, pp. 695–707, 2003.
27. V. Bourdeau, J. Desch nes, R. Mґetivier et al., “Genome-wide identification of high-affinity estrogen response elements in human and mouse,” Molecular Endocrinology, vol. 18, no. 6, pp. 1411–1427, 2004.
28. L. Klein-Hitpass, G.U. Ryffel, E. Heitlinger, and A. C.B. Cato, “A 13 bp palindrome is a functional estrogen responsive element and interacts specifically with estrogen receptor,” Nucleic Acids Research, vol. 16, no. 2, pp. 647–663, 1988.
29. S. Kamalakaran, S.K. Radhakrishnan, and W. T. Beck, “Identification of estrogen-responsive genes using a genomewide analysis of promoter elements for transcription factor binding sites,”The Journal of Biological Chemistry, vol. 280, no. 22, pp. 21491–21497, 2005.
30. A. Scholz, M. Truss, and M. Beato, “Hormone-induced recruitment of Sp1 mediates estrogen activation of the rabbit uteroglobin gene in endometrial epithelium,” The Journal of Biological Chemistry, vol. 273, no. 8, pp. 4360–4366, 1998.
31. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res. 2004 Jan 1; 10 (1 Pt 2): 331S-6S.
32. Shou J, Massarweh S, Osborne CK, et al. 2004. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl. Cancer Inst. 96: 926–35.
33. Wu RC, Smith CL, O’Malley BW. 2005. Transcriptional regulation by steroid receptor coactivator phosphorylation. Endocr. Rev. 26: 393–99.
34. Schiff R, Massarweh S, Shou J, et al. 2003. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin. Cancer Res. 9: 447S-54S.
35. Kushner PJ, Agard DA, Greene GL, et al. 2000. Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol. 74: 311–17.
36. Vyhlidal C, Samudio I, Kladde MP, et al. 2000. Transcriptional activation of transforming growth factor alpha by estradiol: requirement for both a GC-rich site and an estrogen response element half-site. J. Mol. Endocrinol. 24: 329–38.
37. Lee AV, Cui X, Oesterreich S. 2001. Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin. Cancer Res. 7: 4429S-35S, discussion (4411S-12S).
38. Umayahara Y, Kawamori R, Watada H, et al. 1994. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J. Biol. Chem. 269: 16433–42.
39. Nicholson RI, Hutcheson IR, Hiscox SE, et al. 2005. Growth factor signaling and resistance to selective oestrogen receptor modulators and pure antioestrogens: the use of antigrowth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr. Relat. Cancer 12(Suppl. 1): S29–S36.
40. Yarden RI, Wilson MA, Chrysogelos SA. 2001. Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J. Cell Biochem. Suppl. 36:232–46.
41. Newman SP, Bates NP, Vernimmen D, et al. 2000. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene 19:490–97.
42. Massarweh S, Osborne CK, Creighton CJ, et al. 2008. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 68:826–33.
43. Bayliss J, Hilger A, Vishnu P, et al. 2007. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clin. Cancer Res. 13:7029–36.
44. Lopez-Tarruella S, Schiff R. 2007. The dynamics of estrogen receptor status in breast cancer: reshaping the paradigm. Clin. Cancer Res. 13:6921–25.
45. Cui X, Zhang P, Deng W, et al. 2003. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol. Endocrinol. 17:575–88.
46. Cui X, Schiff R, Arpino G, et al. 2005. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J. Clin. Oncol. 23:7721–35.
47. Guo S, Sonenshein GE. 2004. Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. Mol. Cell Biol. 24:8681–90.
48. Creighton CJ, Fu X, Hennessy BT, et al. 2010. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 12(3): R40.
49. Levin ER, Pietras RJ. 2008. Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res. Treat. 108:351–61.
50. Santen RJ, Fan P, Zhang Z, et al. 2009. Estrogen signals via an extranuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells. Steroids 74:586–94.
51. Wu RC, Qin J, Yi P, et al. 2004. Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol. Cell 15:937–49.
52. Lee H, Bai W. 2002. Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol. Cell Biol. 22:5835–45.
53. Pontiggia O, Rodriguez V, Fabris V, et al. 2009. Establishment of an in vitro estrogen-dependent mouse mammary tumor model: a new tool to understand estrogen responsiveness and development of tamoxifen resistance in the context of stromal-epithelial interactions. Breast Cancer Res. Treat. 116:247–55.
54. M. Dowsett, I. E. Smith, S.R. Ebbs et al., “Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer,” Clinical Cancer Research, vol. 12, no.3, part 2, pp. 1024s-1030s, 2006.
55. S. F. Doisneau-Sixou, C.M. Sergio, J.S. Carroll, R. Hui, E.A. Musgrove, and R. L. Sutherland, “Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells,” Endocrine-Related Cancer, vol. 10, no. 2, pp. 179–186, 2003.
56. P. Schick, J. Goodstein, J. Moor, J. Butler, and K. L. Senter, “Preoperative chemotherapy followed by mastectomy for locally advanced breast cancer,” Journal of Surgical Oncology, vol. 22, no. 4, pp. 278–282, 1983.
57. M. Kaufmann, G.N. Hortobagyi, and A. Goldhirsch, “Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update,” Journal of Clinical Oncology, vol. 24, no. 19, p. 3221, 2006.
58. A.K. Shiau, D. Barstad, P.M. Loria et al., “Thestructural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen” Cell, vol. 95, no. 7, pp. 927–937, 1998.
59. C.M. Klinge, S.C. Jernigan, S. L. Smith, V.V. Tyulmenkov, and P.C. Kulakosky, “Estrogen response element sequence impacts the conformation and transcriptional activity of estrogen receptor,”Molecular and Cellular Endocrinology, vol. 174, no. 1–2, pp. 151–166, 2001.
60. X. Long and K.P. Nephew, “Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen recepto” Journal of Biological Chemistry, vol. 281, no. 14, pp. 9607–9615, 2006.
61. A. Howell, J. F.R. Robertson, P. Abram et al., “Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial,” Journal of Clinical Oncology, vol. 22, no. 9, pp. 1605–1613, 2004.
62. A.U. Buzdar, “Fulvestrant – a novel estrogen receptor antagonist for the treatment of advanced breast cancer,” Drugs of Today, vol. 44, no. 9, pp. 679–692, 2008.
63. W.R. Miller, A. Larionov, L. Renshaw et al., “Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole,” Journal of Clinical Oncology, vol.27, no. 9, pp. 1382–1387, 2009.
64. A. Howell and M. Dowsett, “Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens,”Breast Cancer Research, vol. 6, no. 6, pp. 269–274, 2004.
65. W.R. Miller and J. Jackson, “The therapeutic potential of aromatase inhibitors,” Expert Opinion on Investigational Drugs, vol. 12, no. 3, pp. 337–351, 2003.
66. R. Bartsch, Z. Bago-Horvath, A. Berghoff et al., “Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer,” European Journal of Cancer, vol. 48, no. 13, pp. 1932–1938, 2012.
67. Encarnacion CA, Ciocca DR, McGuire WL, et al. 1993. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res. Treat. 26: 237–46.
68. Gutierrez MC, Detre S, Johnston S, et al. 2005. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogenactivated protein kinase. J. Clin. Oncol. 23: 2469–76.
69. Hull DF 3rd, Clark GM, Osborne CK, et al. 1983. Multiple estrogen receptor assays in human breast cancer. Cancer Res. 43: 413–16.
70. Lipton A, Leitzel K, Ali SM, et al. 2005. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 104: 257–63.
71. Meng S, Tripathy D, Shete S, et al. 2004. HER-2 gene amplification can be acquired as breast cancer progresses. Proc. Natl. Acad. Sci. USA 101: 9393–98.
72. Arpino G, Green SJ, Allred DC, et al. 2004. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positivemetastatic breast cancer: a Southwest Oncology Group study. Clin. Cancer Res. 10: 5670–76.
73. Brankovic-Magic M, Jankovic R, Neskovic-Konstantinovic Z, et al. 2002. Progesterone receptor status of breast cancer metastases. J. Cancer Res. Clin. Oncol. 128:55–60.
74. Gross GE, Clark GM, Chamness GC, et al. 1984. Multiple progesterone receptor assays in human breast cancer. Cancer Res. 44:836–40.
75. Dodwell D, Wardley A, Johnston S. 2006. Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors. Breast 15: 584–94.
76. Robertson JF, Osborne CK, Howell A, et al. 2003. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98: 229–38.
77. Milani A, Geuna E, Mittica G, Valabrega G. Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions. World J Clin Oncol. 2014 Dec 10; 5(5): 990–1001. doi: 10.5306/wjco.v5.i5.990.
78. Salvatori L, Pallante P, Ravenna L, Chinzari P, Frati L, Russo MA, Petrangeli E. Oestrogens and selective oestrogen receptor (ER) modulators regulate EGF receptor gene expression through human ER alpha and beta subtypes via an Sp1 site. Oncogene. 2003; 22: 4875–4881.
79. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005; 23: 2469–2476.
80. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009; 9: 631–643.
81. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012; 149: 274–293.
82. Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 2011; 13:224.
83. Dillon RL, White DE, Muller WJ. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene. 2007; 26: 1338–1345.
84. deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.Clin Cancer Res. 2004; 10: 8059–8067.
85. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013; 45: 1439–1445.
86. Di Leo A, Jerusalem G, Petruzelka L, et al: Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. Journal of Clinical Oncology, 2010 V.28 № 30 p.4595–4601; Journal or the National Cancer Institute V. 106 (1): c. 337.
87. Leo A Di, Jerusalem G, Petruzelka L, et al: Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial. Journal or the National Cancer Institute V. 106(1): р. 337.
88. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012 Feb 9; 366(6): 520–9.
89. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, R vil C, Jones A. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009 Nov 20; 27 (33): 5529–37.
90. Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O’Rourke L, Oliva C, Stein S, Pegram M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009 Nov 20; 27 (33): 5538–46.
91. Schwartzberg LS, Franco SX, Florance A, O’Rourke L, Maltzman J, Johnston S. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist. 2010; 15 (2): 122–9.
Для цитирования: Хисамов А.А., Мануйлова О.О., Бяхов М.Ю. Механизмы развития и пути преодоления эндокринной резистентности при раке молочной железы. Злокачественные опухоли. 2015;(4):52-61. https://doi.org/10.18027/2224-5057-2015-4-52-61
For citation: Khisamov A.A., Manujlova O.O., Byakhov M.Y. Mechanisms of development and the ways to overcome endocrine resistance in breast cancer. Malignant tumours. 2015;(4):52-61. (In Russ.) https://doi.org/10.18027/2224-5057-2015-4-52-61
- Обратные ссылки не определены.
Контент доступен под лицензией Creative Commons Attribution 4.0 License.